INTERPACE BIOSCIENCES, INC. (IDXG): restructuring charge — Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage

INTERPACE BIOSCIENCES, INC.

Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.
Workforce reduction announced; severance costs $0.5-0.6M in Q2 plus $0.2M in Q1 2025.
Restructuring to cut annual cost of revenue and OpEx by $12.5-14.5M, offsetting ~1/3 of revenue loss.
Plan substantially complete by end of Q2 2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.95

INTERPACE BIOSCIENCES, INC. announced a restructuring with charges of severance costs in the range of $0.5 million to $0.6 million to be recorded primarily in the second quarter of 2025 which is in addition to the $0.2 million pre affecting workforce reduction (reducing its workforce).

Type: restructuring
Charge: severance costs in the range of $0.5 million to $0.6 million to be recorded primarily in the second quarter of 2025 which is in addition to the $0.2 million pre
Affected area: workforce reduction
Headcount: reducing its workforce

Exact text from the filing

On April 25, 2025, the Company announced implementation of its previously approved restructuring and cost-savings plan to reduce operating costs and better align its workforce with the loss of PancraGEN® (the “Restructuring Plan”).

View on SEC.gov

Browse all restructurings & charges →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001641172-25-007944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.